Related Experiment Videos
[Therapeutic results in children with acute non-lymphoblastic leukemia treated with modified BFM-87 protocol]
Voprosy Onkologii
|January 1, 1997
Insights
Modified BFM-87 treatment in children with acute non-lymphoblastic leukemia achieved 90% complete remission. Despite higher complications, adjuvant therapy lowered mortality rates, improving outcomes for pediatric leukemia patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trials
Context:
- Acute non-lymphoblastic leukemia (ANLL) is a significant challenge in pediatric oncology.
- The BFM-87 treatment schedule is a standard chemotherapy regimen.
- Optimizing treatment protocols is crucial for improving survival rates in children with leukemia.
Purpose:
- To evaluate the effectiveness of a modified BFM-87 treatment schedule in children with ANLL.
- To compare the outcomes of the modified BFM-87 schedule with the standard "7 + 3" protocol.
- To assess remission rates, survival, and complication profiles.
Summary:
- The study involved 32 children with various forms of ANLL treated with a modified BFM-87 schedule since April 1991.
- Complete remission was achieved in 90% of patients.
- Five-year recurrence-free survival was recorded at 47%.
Impact:
- The modified BFM-87 schedule demonstrated a high complete remission rate in pediatric ANLL.
- While the complication rate was higher than the "7 + 3" schedule, adjuvant therapy contributed to lower mortality.
- This modified approach offers a potential improvement in managing childhood acute non-lymphoblastic leukemia.
Abstract:
The effectiveness of modification of the BFM-87 schedule of treatment received by 32 children with different forms of acute non-lymphoblastic leukemia since April, 1991, has been studied. Complete remission was recorded in 90% and 5-year recurrence-free survival--in 47%. Although the complication rate was higher as compared with the "7 + 3" schedule, mortality rates were relatively lower due to application of adjuvant therapy.